{'fraction_non_alphanumeric': 0.021544327931363204, 'fraction_numerical': 0.002669208770257388, 'mean_word_length': 5.428921568627451, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pragmatic Trials for Noncommunicable Diseases: Relieving Constraints

In this month's editorial, PLOS Medicine Editorial Board member Anushka Patel and Ruth Webster discuss how applying rules for drug efficacy trials can impede pragmatic trials of interventions for noncommunicable diseases.

for contextual understanding but not appropriate for classic RCTs that generate data on safety and efficacy. Similarly, those who evaluate research proposals (e.g., peer-review panels of funding agencies, ethics committees, and regulatory bodies) should carefully consider the context and purpose of a pragmatic study and avoid imposing unwarranted conditions that could undermine its potential value. Examples of problematic design features include the following: 1. Strict inclusion and exclusion criteria (other than appropriate criteria based on known safety and efficacy data) that limit generalisability.
2. Implementation of data collection or other trial processes in such a way that substantially alters the study intervention or usual care.
3. Individual consent procedures (where there are no or minimal additional risks compared to usual care) that will likely impede use of an intervention because of the influence of consent procedures on work flow. 4. Specifying "unusual" usual care, namely care which does not reflect typical practice in the environment in which the intervention would be applied.

5.
Restriction of the purchase of goods and services by research participants, particularly where the costs of goods or services are likely to influence uptake in the "real world" context. 6. Strict standardisation of the study intervention to the exclusion of variations that are to be expected following implementation within complex adaptive systems. Context is important in implementation research and can vary substantially between and within health systems and over time. Such variation does not negate the value of investigating effectiveness of the intervention in a pRCT, as long as variations in implementation are captured and adequately described.
7. Attempting to introduce blinding where this is inherently not possible. While lack of blinding can introduce bias particularly in the context of subjective patient-reported outcomes, knowledge of receipt (or lack of receipt) of an intervention may influence behaviour and adoption in "real life" implementation. Capturing such information (e.g., through process evaluations embedded within a pRCT) may be extremely valuable.
8. Inadequate emphasis on outcomes beyond establishing effectiveness that relate to service delivery such as adoption, acceptability, feasibility, fidelity, cost, coverage, and sustainability. Also important might be the measurement of potential unintended consequences of implementing a new intervention within a complex health system.
Examples of some of these challenges can be found in a range of research studies that aimed to understand the potential role of fixed-dose combination drugs ("polypills") in reducing the treatment gaps among people at high risk of cardiovascular disease, in whom safety and efficacy of component medications is established, with guidelines universally recommending their use. It has been theorised that implementation strategies that utilise polypills with generic components may help reduce treatment gaps by reducing costs and complexity of drug regimens. A pilot trial conducted in Sri Lanka failed to demonstrate benefits of a polypill-based strategy over "standard care" in terms of blood pressure and cholesterol reduction; however, standard care as implemented in this trial was subsequently found to be highly unusual, with much greater use of recommended medications compared to known "real world" practice patterns [5]. To some extent, this may have been driven by changes to standard care introduced only in the context of the trial. In a large pRCT of a polypill-based strategy in the UK and India, the polypill was provided for free (as this was defined as the "study drug"), while usual care participants may not have received similar subsidies [6]. If cost of treatment is a real impediment to appropriate drug use, this difference may lead to inaccurate assumptions about "real world" effectiveness.
These issues are not all easily addressed, but more awareness, consideration, and debate are required to maximise the value of pRCTs, which represent one important type of implementation research. Careful consideration of these issues is important not only for researchers developing and conducting pRCTs but also for those responsible for approving proposed research. Clinical trial activity is usually assessed within ethics and regulatory frameworks that are primarily designed for efficacy studies of new drugs and devices. A regulatory burden that is disproportionate to the typical level of risk in pRCTs evaluating implementation of treatments of known safety and efficacy can seriously undermine the usefulness of such research. For NCDs, pRCTs are important to identify the best way to implement the plethora of available effective preventive interventions. If current constraints are not addressed, meeting many of the 2025 voluntary goals for NCD control may be even more challenging.